
Bradley Mills, Ph.D., and Scott Gerber, Ph.D., in the Gerber Lab
Wilmot Cancer Institute research team reports that combining a type of radiation therapy with immunotherapy not only cures pancreatic cancer in mice, but appears to reprogram the immune system to create an “immune memory” in the same way that a vaccine keeps the flu away.
The result is that the combination treatment also destroyed pancreatic cells that had spread to the liver, a common site for metastatic disease.
The journal Cell Reports published the study, with Scott Gerber, Ph.D., as corresponding author, and Bradley Mills, Ph.D., a post-doctoral fellow in the Gerber Lab, as first author. They led a large team of collaborators from the University of Rochester departments of Surgery, Microbiology and Immunology, Pathology and Laboratory Medicine, Radiation Oncology, and Environmental Medicine.
Pancreatic cancer is aggressive and generally has poor survival odds. It’s been in the news this year after “Jeopardy!” host Alex Trebek went public with his diagnosis and treatment. In more than 80 percent of patients, the cancer is discovered in later stages when surgery is not an option and chemotherapy is usually not effective beyond stabilizing the disease.
Pancreatic tumors are notoriously hard to treat because they are surrounded by a toxic stew of proteins and other tissues that protect the cancer cells from the immune system’s natural role to attack invaders.
Wilmot researchers looked for an innovative treatment combination that could do two things at once: activate T-cells to attack the cancer and convert the immune-suppressing cells into fighters, the study said.
The combination they used in laboratory models consisted of stereotactic body radiotherapy (SBRT), which delivers high doses of radiation over a short period of time and may also prime the immune system to kill cancer cells; and interleukin-12 (IL-12), which has well-known anti-cancer activity and also activates the immune system. However, IL-12 often comes with harsh side effects. To solve that problem, researchers are testing a timed-release technology in a specially designed mouse model for pancreatic cancer, which would slowly deliver the drug over two weeks.
The preclinical laboratory investigation resulted in Gerber’s team receiving a $2 million National Cancer Institute grant in July to continue the research, which includes moving the findings into clinical trials in the future. Gerber is an assistant professor and co-director of the Center for Tumor Immunology Research.
Learn more: Study: Innovative Pancreatic Cancer Treatment May Rev Up Immune System
The Latest on: Pancreatic cancer treatment
[google_news title=”” keyword=”pancreatic cancer treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pancreatic cancer treatment
- Novartis Precision Cancer Therapy Hits Primary Goal In Rare Type Of Pancreatic Canceron September 25, 2023 at 4:14 am
Novartis AG (NYSE: NVS) released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- 'I'm a GP - here are the first red flag signs of pancreatic cancer'on September 23, 2023 at 10:00 pm
He said: "The first red flag signs of pancreatic cancer are often unexplained weight loss, jaundice and/or back /stomach pain." When it comes to unexplained weight loss he explained: "If you find ...
- Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncologyon September 21, 2023 at 2:07 am
Raffaele Baffa, MD, PhD, Chief Medical Officer of CARsgen Therapeutics, remarked that, "I am delighted to see the publication of two cases on our CT041's treatment of metastatic pancreatic cancer ...
- Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncologyon September 21, 2023 at 1:20 am
Get 7 Days Free Sign In Sign In Topics ...
- Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncologyon September 21, 2023 at 1:09 am
Raffaele Baffa, MD, PhD, Chief Medical Officer of CARsgen Therapeutics, remarked that, "I am delighted to see the publication of two cases on our CT041's treatment of metastatic pancreatic cancer ...
- Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncologyon September 21, 2023 at 1:00 am
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the ...
- Advancements In Pancreatic Cancer Treatment: Biotech Innovations And Rising Optimismon September 19, 2023 at 1:31 pm
Advancements in Pancreatic Cancer Treatment: Biotech Innovations and Rising Optimism . News Group – According to the American Cancer Society in its Cancer ...
- Pancreatic Cancer Battle Boosted By $200M VC Firmon September 19, 2023 at 10:11 am
FN Media Group Presents News Group News Commentary VANCOUVER, BC, Sept. 19, 2023 /PRNewswire/ -- News Group - A new ...
- Investing in Hope: Reed Jobs, the Cancer Moonshot, and the Future of Pancreatic Cancer Treatmenton September 19, 2023 at 8:51 am
Reed Jobs, son of the late Apple creator Steve Jobs, has become a beacon of hope in the fight against pancreatic cancer. His venture capital firm Yosemite is investing in new cancer treatments. And ...
- Cancer changed my macho views on accepting helpon September 19, 2023 at 1:57 am
When Andy Segal got his cancer diagnosis, he didn’t want to accept help from anyone. He soon learned the value of that help from his devoted family and friends.
via Bing News